Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer.

J Exp Med

Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.

Published: January 2020

IL-15, a pleiotropic cytokine, stimulates generation of NK, NK-T, γδ, ILC1, and memory CD8 T cells. IL-15 disorders play pathogenetic roles in organ-specific autoimmune diseases including celiac disease. Diverse approaches are developed to block IL-15 action. IL-15 administered to patients with malignancy yielded dramatic increases in NK numbers and modest increases in CD8 T cells. Due to immunological checkpoints, to achieve major cancer therapeutic efficacy, IL-15 will be used in combination therapy, and combination trials with checkpoint inhibitors, with anti-CD40 to yield tumor-specific CD8 T cells, and with anticancer monoclonal antibodies to increase ADCC and antitumor efficacy, have been initiated.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037239PMC
http://dx.doi.org/10.1084/jem.20191062DOI Listing

Publication Analysis

Top Keywords

cd8 cells
12
il-15
5
interleukin-15 dysregulation
4
dysregulation lymphoid
4
lymphoid homeostasis
4
homeostasis implications
4
implications therapy
4
therapy autoimmunity
4
autoimmunity cancer
4
cancer il-15
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!